Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $235,572.67 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 1,541 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $235,572.67. Following the transaction, the chief executive officer now owns 136,778 shares in the company, valued at approximately $20,909,252.86. This represents a 1.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kyle Gano also recently made the following trade(s):

• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00.

Neurocrine Biosciences Price Performance

NBIX stock opened at $150.51 on Friday. The company has a market capitalization of $15.24 billion, a P/E ratio of 40.35 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98. The firm’s fifty day simple moving average is $138.41 and its 200-day simple moving average is $131.64.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 3.92 earnings per share for the current year.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Golden State Wealth Management LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter worth approximately $25,000. Brooklyn Investment Group increased its holdings in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the period. Lindbrook Capital LLC boosted its holdings in Neurocrine Biosciences by 53.5% during the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock worth $51,000 after buying an additional 130 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at $61,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on NBIX shares. HC Wainwright reissued a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. BMO Capital Markets reduced their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. UBS Group raised their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Piper Sandler reiterated an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Finally, Raymond James restated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $166.85.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.